Staphylococcus aureus: Current Progress in Vaccines and Host-Pathogen Interaction
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Pathogens-host Immune Interface".
Deadline for manuscript submissions: closed (27 September 2023) | Viewed by 278
Special Issue Editors
Interests: pathogenesis of Staphylococcus aureus and Staphylococcus epidermidis; host–pathogen interaction; bacteriophage
Interests: pathogenesis of clinical pathogens and host defense
Special Issue Information
Dear Colleagues,
Staphylococcus aureus infections are one of the leading causes of mortality in both hospital and community settings. The widespread distribution of methicillin-resistant S. aureus (MRSA) worldwide reinforces the need for new prevention and treatment strategies such as vaccines and antibiotics. However, all attempts at vaccines against S. aureus have failed so far. Although making a successful S. aureus vaccine has proven challenging, scientists in the research community never give up on investigation and development in this field, looking into many S. aureus virulence mechanisms by studying host–pathogen interactions, establishing animal models that better mimic human conditions during infection, enrolling more populations at risk of S. aureus infection, discovering new virulence and immune-evasion factors, and looking into both humoral and cellular aspects of the human immune system.
This Special Issue of Vaccines aims to collect recent findings on S. aureus vaccine research and host–pathogen interactions to catalyze novel approaches for the development of vaccines against S. aureus. Original scientific research articles, method papers, case reports, reviews and short communications are welcome.
Research areas may include (but are not limited to) the following:
- Host–pathogen interaction;
- Immune response;
- Immune evasion;
- Virulence factors;
- Targeted vaccine delivery;
- Statistical and mathematical models in vaccine development;
- Clinical trials;
- Vaccine dose and immunization regimens;
- Structural biology;
- Vaccine efficacy;
- Animal models;
- Pathogenesis;
- Novel vaccine targets.
We warmly welcome all scientists working in these fields to submit their manuscripts to our Special Issue.
We are looking forward to receiving your contributions.
Dr. Xin Du
Dr. Qian Liu
Dr. Shiping Lu
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
